July 2, 2014
A newly published article on pigprogress.net by Anne Mette
Strunz Hanl, DVM, Ø-Vet A/S, Denmark talks about modern swine
production facilities, with high production figures,
where anaemia has become an issue once more.
The article focuses on the increased productivity in
modern swine production and a potential iron gap as a result of
that.
Well-known Prof Robert Friendship, Ontario Veterinary
College, University of Guelph, Canada is quoted in the article for
saying that there are several factors that are
responsible for the increased iron deficiency-induced
anaemia:
- Increased litter sizes resulting in lower iron stores at
birth
- Increased spread in birth weights and growth rates as a direct
consequence
- Accelerated growth rates for piglets born with above-average
birth weights result in increased risk of depletion of available
iron stores
- Low levels of iron in the sow's milk are diminished to even
lower levels with the increased litter sizes.
The article also deals with the subject "Turning risk into
and advantage" and "Detecting and treating anaemia.
Read the full article on pigprogress.net - Click here
About Uniferon
Uniferon is a modern improved iron hydrogenated dextran based on
a natural formula, which is approved for global use:
Uniferon is manufactured without the use of any organic solvents
or cyanide, thus, avoiding trace residues of these impurities.
Pharmacosmos manufactures iron dextran of high quality and unique
purity for customers worldwide. Uniferon is the only injectable
iron brand for piglets approved in the EU, the US and Asia.
About Pharmacosmos
Headquartered in Denmark, Pharmacosmos is a family-owned,
international healthcare company with more than 50 years of
innovation and leadership in iron- and carbohydrate-based
treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses
on improving the lives of patients with iron deficiency with or
without anaemia. More than 1 billion people live with iron
deficiency anaemia and it is the leading cause of death for an
estimated 180,000 people every year. This makes it one of the
largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, the UK and the US
and its products are marketed in more than 80 countries across the
world. Its manufacturing facilities are approved, among others, by
the Danish Medicines Agency and the US FDA.